Quotes 5-day view Delayed Nasdaq
10/20/2020
10/21/2020
10/22/2020
10/23/2020
10/26/2020
Date
392.43(c)
387.84(c)
395.795(c)
411(c)
418 Last
814 754
764 008
464 495
548 242
894 836 Volume
-1.28% -1.17% +2.05% +3.84% +1.70% Change
Sales 2020
1 874 M - -
Net income 2020
175 M - -
Net Debt 2020
132 M - -
P/E ratio 2020
230x
Yield 2020
-
Sales 2021
2 304 M - -
Net income 2021
285 M - -
Net cash position 2021
354 M - -
P/E ratio 2021
142x
Yield 2021
-
Capitalization
39 350 M 39 350 M -
EV / Sales 2020
21,1x
EV / Sales 2021
16,9x
Nbr of Employees
3 900
Free-Float
98,8%
DexCom, Inc. specialises in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 78.7% of net sales.
Notations Surperformance© of DexCom, Inc.
Trading Rating : Investor Rating :
All news about DEXCOM, INC.
News in other languages on DEXCOM, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends DEXCOM, INC.
Short Term Mid-Term Long Term Trends Neutral Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
21
Average target price
457,26 $
Last Close Price
411,00 $
Spread / Highest target
31,4%
Spread / Average Target
11,3%
Spread / Lowest Target
-49,6%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
